We show that GITR-mediated checkpoint stimulation ameliorates TIL functionality and anti-PD1-mediated TIL reinvigoration, thereby providing rationale for immunotherapies targeting GITR in pMMR CRC and CRLM patients. This evidence concerns the gene PDCD1 and colorectal carcinoma.